PINK
FSNUY

Fresenius SE & Co KGaA ADR

Medical Care Facilities
Healthcare

Prices are adjusted according to historical splits.

Fresenius SE & Co KGaA ADR Stock Price

Vitals

Today's Low:
$7.63
Today's High:
$7.72
Open Price:
$7.65
52W Low:
$4.6315
52W High:
$8.27
Prev. Close:
$7.55
Volume:
28677

Company Statistics

Market Cap.:
$17.39 billion
Book Value:
8.9155
Revenue TTM:
$41.69 billion
Operating Margin TTM:
7.08%
Gross Profit TTM:
$10.73 billion
Profit Margin:
2.4%
Return on Assets TTM:
2.42%
Return on Equity TTM:
4.99%

Company Profile

Fresenius SE & Co KGaA ADR had its IPO on under the ticker symbol FSNUY.

The company operates in the Healthcare sector and Medical Care Facilities industry. Fresenius SE & Co KGaA ADR has a staff strength of 315,233 employees.

Stock update

Shares of Fresenius SE & Co KGaA ADR opened at $7.65 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $7.63 - $7.72, and closed at $7.72.

This is a +2.25% increase from the previous day's closing price.

A total volume of 28,677 shares were traded at the close of the day’s session.

In the last one week, shares of Fresenius SE & Co KGaA ADR have slipped by -3.86%.

Fresenius SE & Co KGaA ADR's Key Ratios

Fresenius SE & Co KGaA ADR has a market cap of $17.39 billion, indicating a price to book ratio of 0.7088 and a price to sales ratio of 0.3809.

In the last 12-months Fresenius SE & Co KGaA ADR’s revenue was $41.69 billion with a gross profit of $10.73 billion and an EBITDA of $4.67 billion. The EBITDA ratio measures Fresenius SE & Co KGaA ADR's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Fresenius SE & Co KGaA ADR’s operating margin was 7.08% while its return on assets stood at 2.42% with a return of equity of 4.99%.

In Q2, Fresenius SE & Co KGaA ADR’s quarterly earnings growth was a negative -79.1% while revenue growth was a positive 3.4%.

Fresenius SE & Co KGaA ADR’s PE and PEG Ratio

Forward PE
7.8003
Trailing PE
16.0833
PEG
1.0103

Its diluted EPS in the last 12-months stands at $0.48 per share while it has a forward price to earnings multiple of 7.8003 and a PEG multiple of 1.0103. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Fresenius SE & Co KGaA ADR’s profitability.

Fresenius SE & Co KGaA ADR stock is trading at a EV to sales ratio of 1.089 and a EV to EBITDA ratio of 6.4573. Its price to sales ratio in the trailing 12-months stood at 0.3809.

Fresenius SE & Co KGaA ADR stock pays annual dividends of $0.92 per share, indicating a yield of 3.28% and a payout ratio of 32.83%.

Balance sheet and cash flow metrics

Total Assets
$76.41 billion
Total Liabilities
$16.06 billion
Operating Cash Flow
$0
Capital Expenditure
$441 million
Dividend Payout Ratio
32.83%

Fresenius SE & Co KGaA ADR ended 2024 with $76.41 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $76.41 billion while shareholder equity stood at $20.09 billion.

Fresenius SE & Co KGaA ADR ended 2024 with $0 in deferred long-term liabilities, $16.06 billion in other current liabilities, 563000000.00 in common stock, $0 in retained earnings and $30.99 billion in goodwill. Its cash balance stood at $2.47 billion and cash and short-term investments were $2.47 billion. The company’s total short-term debt was $5,020,000,000 while long-term debt stood at $17.60 billion.

Fresenius SE & Co KGaA ADR’s total current assets stands at $19.31 billion while long-term investments were $0 and short-term investments were $0. Its net receivables were $7.76 billion compared to accounts payable of $1.93 billion and inventory worth $5.02 billion.

In 2024, Fresenius SE & Co KGaA ADR's operating cash flow was $0 while its capital expenditure stood at $441 million.

Comparatively, Fresenius SE & Co KGaA ADR paid $0.33 in dividends in 2024.

Other key metrics

Current Trading Price
$7.72
52-Week High
$8.27
52-Week Low
$4.6315
Analyst Target Price
$

Fresenius SE & Co KGaA ADR stock is currently trading at $7.72 per share. It touched a 52-week high of $8.27 and a 52-week low of $8.27. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $7.67 and 200-day moving average was $7.04 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0.8% are held by institutions.

Frequently Asked Questions About Fresenius SE & Co KGaA ADR

The stock symbol (also called stock or share ticker) of Fresenius SE & Co KGaA ADR is FSNUY

The IPO of Fresenius SE & Co KGaA ADR took place on

Similar Industry Stocks (Medical Care Facilities)

Last Price
Chg
Chg%
$1.8
-0.18
-9.09%
$289.45
-9.6
-3.21%
$16.67
-0.13
-0.77%
$189.45
-13.85
-6.81%
$18.95
-0.05
-0.26%
KeyCorp (KEY)
$11.77
0.56
+5%
$266.4
26.1
+10.86%
$3.66
0.01
+0.27%
$10.83
-0.23
-2.08%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Address

Else-Kroener-Strasse 1, Bad Homburg vor der Höhe, Germany, 61352